Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2062Y] to Synaptojanin 2
- Suitable for: WB, IP, ICC
- Reacts with: Human
Product nameAnti-Synaptojanin 2 antibody [EPR2062Y]
See all Synaptojanin 2 primary antibodies
DescriptionRabbit monoclonal [EPR2062Y] to Synaptojanin 2
Tested applicationsSuitable for: WB, IP, ICCmore details
Unsuitable for: Flow Cyt or IHC-P
Species reactivityReacts with: Human
Synthetic peptide within Human Synaptojanin 2 aa 1-100 (N terminal). The exact sequence is proprietary.
- SH-SY5Y cell lysate
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab75880 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500. Predicted molecular weight: 166 kDa.|
|ICC||Use at an assay dependent dilution.|
FunctionInositol 5-phosphatase which may be involved in distinct membrane trafficking and signal transduction pathways. May mediate the inhibitory effect of Rac1 on endocytosis.
Sequence similaritiesBelongs to the synaptojanin family.
In the central section; belongs to the inositol-1,4,5-trisphosphate 5-phosphatase family.
Contains 1 RRM (RNA recognition motif) domain.
Contains 1 SAC domain.
Cellular localizationMembrane. Predominantly associated with the particulate fractions.
- Information by UniProt
- 4 antibody
- 5-trisphosphate 5-phosphatase 2 antibody
- Inositol phosphate 5' phosphatase 2 antibody
Anti-Synaptojanin 2 antibody [EPR2062Y] (ab75880) at 1/500 dilution + SH-SY5Y cell lysate
at 10 µg
Goat anti rabbit-HRP at 1/1000 dilution
Predicted band size: 166 kDa
Observed band size: 140 kDa why is the actual band size different from the predicted?
ab75880 has not yet been referenced specifically in any publications.